CN100393321C - Oral antilipemic liquid and its preparing method - Google Patents
Oral antilipemic liquid and its preparing method Download PDFInfo
- Publication number
- CN100393321C CN100393321C CNB200610170477XA CN200610170477A CN100393321C CN 100393321 C CN100393321 C CN 100393321C CN B200610170477X A CNB200610170477X A CN B200610170477XA CN 200610170477 A CN200610170477 A CN 200610170477A CN 100393321 C CN100393321 C CN 100393321C
- Authority
- CN
- China
- Prior art keywords
- test
- chitosan
- polydextrose
- group
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims description 15
- 230000002402 anti-lipaemic effect Effects 0.000 title abstract description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 82
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 78
- 229920001661 Chitosan Polymers 0.000 claims abstract description 50
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 41
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 41
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 39
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 39
- 239000011718 vitamin C Substances 0.000 claims abstract description 39
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 79
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 229920001100 Polydextrose Polymers 0.000 claims description 39
- 239000001259 polydextrose Substances 0.000 claims description 39
- 235000013856 polydextrose Nutrition 0.000 claims description 39
- 229940035035 polydextrose Drugs 0.000 claims description 39
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 31
- 230000001603 reducing effect Effects 0.000 claims description 23
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 16
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 16
- 235000009392 Vitis Nutrition 0.000 claims description 16
- 241000219095 Vitis Species 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- 239000002002 slurry Substances 0.000 claims description 16
- 240000000560 Citrus x paradisi Species 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 114
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 79
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 44
- 241000700159 Rattus Species 0.000 description 34
- 239000000243 solution Substances 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 29
- 235000012000 cholesterol Nutrition 0.000 description 28
- 108010023302 HDL Cholesterol Proteins 0.000 description 23
- 230000037396 body weight Effects 0.000 description 23
- 230000008859 change Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 235000013305 food Nutrition 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 239000004380 Cholic acid Substances 0.000 description 7
- 229960002471 cholic acid Drugs 0.000 description 7
- 235000019416 cholic acid Nutrition 0.000 description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000000556 factor analysis Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 231100000460 acute oral toxicity Toxicity 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 206010061619 Deformity Diseases 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010013183 Dislocation of vertebra Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010054033 Chitin deacetylase Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 235000015073 liquid stocks Nutrition 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 235000019313 oat gum Nutrition 0.000 description 1
- 239000001912 oat gum Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a kind of oral antilipemic liquid with good taste and no toxic side effect and its preparation process. The oral antilipemic liquid contains in each 100 ml xylose oligomer 4-8 g, glucose polymer 2-6 g, chitosan 1-4 g and vitamin C 0.1-0.5 g. Both animal and human body experiments show that the oral antilipemic liquid of the present invention has no toxic side effect and obvious antilipemic effect.
Description
Technical field
The present invention relates to a kind of health-care products, relate in particular to a kind of oral liquid and preparation method thereof, belong to field of health care products with blood fat reducing function.
Background technology
Blood fat is the general name of contained lipid material in the blood.If hyperlipoidemia causes blood thick easily, on blood vessel wall, deposit, form little speckle gradually, these specklees increase, increase, and artery-clogging makes blood flow slack-off gradually, and blood flow is interrupted when serious.If this situation occurs in heart, just cause coronary heart disease; Occur in brain, apoplexy will occur.
Generally acknowledged hyperlipemia at present, comprise that hypercholesterolemia, hypertriglyceridemia and plyability hyperlipemia are one of main hazard factors of promotion atherosclerosis and the coronary atherosclerotic heart disease (CHD) that jeopardizes human health, and blood fat reducing can reduce the incidence rate of coronary atherosclerotic heart disease.Data shows according to statistics, and every hypercholesterolemia reducing level is equal 1%, can reduce the incidence rate of 2% myocardial infarction.In addition, the reduction of blood fat has been proved the progress of established atherosclerotic plaque that can slow down, even it is disappeared, and might lower the case fatality rate of coronary atherosclerotic heart disease.
Treatment is to change unusual blood fat situation and reduce the risk that coronary heart disease takes place with the significance of control hyperlipemia, and Therapeutic Method generally is divided into Drug therapy and non-drug therapy two aspects.The control of hyperlipemia generally needs to carry out for a long time even throughout one's life, required appropriate litigation fees costliness, and all fat-reducing medicaments all have certain toxic and side effects at present, and part Study data result shows that pharmaceutical intervention (being non-that spit of fland class lipid lowerers especially) can not make crowd's general mortality rate reduce.Therefore, provide a kind of having no side effect, have auxiliary lipid-lowering function effect preferably and mouthfeel and local flavor easily is that the health-care products that the patient accepted has important practical significance.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, provides a kind of and has no side effect, effectively blood fat reducing and mouthfeel and all good oral liquids of local flavor.
Technical problem to be solved by this invention is achieved through the following technical solutions:
A kind of oral administration liquor for reducing blood fat, per 100 milliliters of these oral liquids contain the component of following weight:
Oligomeric xylose 4-8g, polydextrose 2-6g, chitosan 1-4g and vitamin C 0.1-0.5g;
Preferably, the weight of above-mentioned each component is: oligomeric xylose 6g, polydextrose 4g, chitosan 2.7g and vitamin C 0.3g.
In order to reach better effect from health care, mouthfeel and local flavor, the per 100 milliliters of components that also can contain following weight of oral administration liquor for reducing blood fat of the present invention: maltose 2-6g, fruit Fructus Vitis viniferae slurry 2-6g, Mel 2-4g, citric acid 0.5-2g, lactic acid 0.05-0.5g, grapefruit essence 0.05-0.5g.
Preferably, the weight of each component is: maltose 4g, fruit Fructus Vitis viniferae slurry 4g, Mel 3g, citric acid 1g, lactic acid 0.1g, grapefruit essence 0.1g.
Oral liquid of the present invention adds animal fiber (chitosan) with water-solubility vegetable fibres (polydextrose) and forms with other active component (vitamin C, oligomeric xylose etc.) cooperation.
Oligomeric xylose: claiming few xylose again, is a kind of good bacillus bifidus increment factor.The function of oligomeric xylose increment bacillus bifidus is other poly-and sugared 20 times, and for the liver road dual regulation is arranged, and constipation or dysentery situation are eased.Oligomeric xylose can improve intestinal flora, promotes intestinal peristalsis promoting, and aggravation food suppresses the poisonous tunning of enteral and generates, thereby have the effect of cholesterol reducing by intestinal, and oligomeric xylose has the effect of blood fat reducing preferably.
Polydextrose: polydextrose is a kind of good water soluble dietary fiber, is a kind of β-1,6 glucosan.Its physiological hygiene function produces short-chain fatty acid for to ferment in large intestine, increase faecal volume, reduces the gastric emptying time, and polydextrose can prevent the heavily absorption of cholesterol and this steroid of Dihydrocholesterol.Polydextrose forms mucous layer at small intestinal, effectively hinders the absorption at small intestinal of triglyceride and cholesterol; Polydextrose can combine with cholic acid, increases bilirubin and discharges, and reduces the formation of cholesterol, also can make body utilize cholesterol to synthesize cholic acid by forming gel absorption cholic acid, reduces serum cholesterol.
Chitosan: claim chitosan, chitosan etc. again.Chitosan is positively charged cation animal food fiber, is again the alkaline polysaccharide of the unique existence of nature, thereby has determined it to have the important physical function.The T-CHOL in the blood and the too high levels of triglyceride can be brought out various cardiovascular diseasess, are directly threatening people's life.The digestion of lipid needs bile acid as emulsifying agent in the food, electropositive chitosan with excrete after the bile acid of negative charge combines, make fat not emulsified, thereby hinder digesting and assimilating of fat.Reduce because of cholesterol mainly is converted into bile acid in liver, this just promotes that liver changes into bile acid with cholesterol, thereby cholesterolemia is reduced.At external a certain proportion of chitosan complexation bile acid preferably, interference body is to the absorption of fat, and chitin disturbs the function of fat absorption.
Vitamin C: vitamin C (VC) is an important Reducing agent in the human body, participates in multiple oxidation-reduction process.Have 80% to be converted into cholic acid and to excrete approximately at normal human's inner cholesterol, VC participates in also promoting its conversion process.When suffering from hypercholesterolemia, therefore the VC that the metabolic exhaustion of cholesterol is a large amount of in time replenishes effectively hypercholesterolemia reducing of an amount of VC.
Polydextrose can form a skim in small intestinal, and swathes the part food fat, can effectively limit the absorption of fat in the digestive tract, promote the drainage of lipids, and increase satiety, it is heavy to reduce feed, thereby reach blood lipid regulation, reduce athero, effects such as prevent obesity.Polydextrose energy absorption of bile acid, organic molecules such as cholesterol mutagen suppress T-CHOL (TG) concentration and raise, and reduce the synthetic of cholic acid and its esters and absorb, reduce human plasma and liver cholesterol levels, the sticky and prevention cardiovascular and cerebrovascular disease of control blood.
Chitosan is a kind of natural polysaccharose substance, is to be present in the chitin deacetylase acyl group in the shells of Crustaceans such as shrimp Eriocheir sinensis and the poly-glucosamine that dissolves in acidic aqueous solution that obtains, has better biocompatibility, has no side effect substantially.Take chitosan and can suppress the rising of plasma cholesterol.
Chitosan is a kind of weak anionite, chitosan derivatives to the binding ability of cholic acid along with the alkyl carbon chain that 6-O-joined increases and increases.Show that the hydrophobicity of positive charge and chitosan 6-O-alkyl is playing an important role aspect the binding ability of cholic acid and certain effect for reducing blood fat is arranged on the chitosan skeleton.Chitosan also is a kind of polysaccharide cellulose of viscosity, with the similar characteristic that can postpone play effect for reducing fat by the emptying of stomach such as oat gum.Chitosan can reduce cholesterol in little intestinal absorption, increases the defecate of neutral sterin, while energy triglyceride reducing, and the absorption of liposoluble substances such as cholesterol reduces, and reaches the accent blood fat thereupon having increased drainage.
Vitamin C and chitosan suppress the synergistic function of having digested and assimilated of fat, find by test, if continue to give in a large number chitosan and sodium Vitamin C when giving the rat high fat diet, rat obviously can be suppressed aspect the fat digestion absorption.
Oligomeric xylose is difficult to be decomposed by the intravital digestive enzyme of people, produce power hardly, and suitable especially obesity, diabetes, hypertension, the arteriosclerotic takes.It has the effect of bifidus factor, and the selectivity of its propagation bacillus bifidus is higher than other functional oligoses; The conformability of it and food is good, only needs to add a little, can promote the absorption of calcium, reaches health-care effect; In addition, oligomeric xylose can also prevent constipation.
The present invention is oligomeric xylose, polydextrose, chitosan and vitamin C according to a certain percentage compatibility together after, have synergistic function each other, play the remarkable health-care effect of blood-fat-decreasing jointly.
Another technical problem to be solved by this invention provides a kind of method for preparing oral liquid of the present invention.
Another technical problem to be solved by this invention is achieved through the following technical solutions:
A kind of method for preparing oral liquid of the present invention may further comprise the steps:
(1) takes by weighing each component by following weight: oligomeric xylose 4-8g, polydextrose 2-6g, chitosan 1-4g and vitamin C 0.1-0.5g;
(2) pure water is heated to 60-70 ℃ after, add oligomeric xylose while stirring, polydextrose, chitosan is until whole dissolvings;
(3) the resulting solution of step (2) was heated 10-20 minute under 80-90 ℃ of temperature, be cooled to room temperature, standby;
(4) with vitamin C with dissolved in purified water after, join in step (3) prepared solution, stir, add pure water to 100ml, stir, filter, filtrate fill, sterilization, promptly.
In the above-mentioned preparation method, preferably pure water is heated to 65 ℃ in the step (2) after, add oligomeric xylose while stirring, polydextrose, chitosan; Preferably the resulting solution of step (2) was heated 15 minutes under 85 ℃ of temperature in the step (3).
Preferred, a kind of method for preparing oral liquid of the present invention may further comprise the steps:
(1) takes by weighing each component by following weight: oligomeric xylose 4-8g, polydextrose 2-6g, chitosan 1-4g and vitamin C 0.1-0.5g, maltose 2-6g, fruit Fructus Vitis viniferae slurry 2-6g, Mel 2-4g, citric acid 0.5-2g, lactic acid 0.05-0.5g and grapefruit essence 0.05-0.5g;
(2) pure water is heated to 60-70 ℃ after, add oligomeric xylose while stirring, polydextrose, chitosan, maltose, fruit Fructus Vitis viniferae slurry, Mel, citric acid and lactic acid are until whole dissolvings;
(3) the resulting solution of step (2) was heated 10-20 minute under 80-90 ℃ of temperature, be cooled to room temperature, standby;
(4) with vitamin C with dissolved in purified water after, join in step (3) prepared solution, stir, add grapefruit essence, add pure water to 100ml, stir, filter, filtrate fill, sterilization, promptly.
In the above-mentioned preparation method, preferably pure water is heated to 65 ℃ in the step (2) after, add oligomeric xylose while stirring, polydextrose, chitosan, maltose, fruit Fructus Vitis viniferae slurry, Mel, citric acid and lactic acid; Preferably the resulting solution of step (2) was heated 15 minutes under 85 ℃ of temperature in the step (3).
The specific embodiment
Further describe the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
Embodiment 1
Take by weighing each component by following weight:
Oligomeric xylose 6kg, polydextrose 4kg, chitosan 2.7kg and vitamin C 0.3kg, maltose 4kg, fruit Fructus Vitis viniferae slurry 4kg, Mel 3kg, citric acid 1kg, lactic acid 0.1kg, grapefruit essence 0.1kg;
After pure water is heated to 65 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, maltose, fruit Fructus Vitis viniferae slurry, Mel, citric acid and lactic acid, until whole dissolvings, then heating 15 minutes under 85 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add grapefruit essence, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up in packing, every 100ml oral liquid contains: oligomeric xylose 6g, polydextrose 4g, chitosan 2.7g and vitamin C 0.3g, maltose 4g, fruit Fructus Vitis viniferae slurry 4g, Mel 3g, citric acid 1g, lactic acid 0.1g, grapefruit essence 0.1g).
Embodiment 2
Take by weighing each component by following weight:
Oligomeric xylose 4kg, polydextrose 2kg, chitosan 1kg and vitamin C 0.1kg, maltose 2kg, fruit Fructus Vitis viniferae slurry 2kg, Mel 2kg, citric acid 0.5kg, lactic acid 0.05kg, grapefruit essence 0.05kg;
After pure water is heated to 60 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, maltose, fruit Fructus Vitis viniferae slurry, Mel, citric acid and lactic acid, until whole dissolvings, then heating 20 minutes under 80 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add grapefruit essence, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up in packing, every 100ml oral liquid contains oligomeric xylose 4g, polydextrose 2g, chitosan 1g and vitamin C 0.1g, maltose 2g, fruit Fructus Vitis viniferae slurry 2g, Mel 2g, citric acid 0.5g, lactic acid 0.05g, grapefruit essence 0.05g).
Embodiment 3
Take by weighing each component by following weight:
Oligomeric xylose 8kg, polydextrose 6kg, chitosan 4kg and vitamin C 0.5kg, maltose 6kg, fruit Fructus Vitis viniferae slurry 6kg, Mel 4kg, citric acid 2kg, lactic acid 0.5kg, grapefruit essence 0.5kg;
After pure water is heated to 75 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, maltose, fruit Fructus Vitis viniferae slurry, Mel, citric acid and lactic acid, until whole dissolvings, then heating 10 minutes under 90 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add grapefruit essence, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up, and every 100ml oral liquid contains: oligomeric xylose 8g in packing, polydextrose 6g, chitosan 4g, vitamin C 0.5g, maltose 6g, fruit Fructus Vitis viniferae slurry 6g, Mel 4g, citric acid 2g, lactic acid 0.5g, grapefruit essence 0.5g).
Embodiment 4
Take by weighing each component by following weight:
Oligomeric xylose 6kg, polydextrose 4kg, chitosan 2.7kg and vitamin C 0.3kg;
After pure water is heated to 60 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, until whole dissolvings, then heating 15 minutes under 85 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up, and every 100ml oral liquid contains: oligomeric xylose 6g in packing, polydextrose 4g, chitosan 2.7g and vitamin C 0.3g).
Embodiment 5
Take by weighing each component by following weight:
Oligomeric xylose 4kg, polydextrose 2kg, chitosan 1kg and vitamin C 0.1kg;
After pure water is heated to 65 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, until whole dissolvings, then heating 15 minutes under 85 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up, and every 100ml oral liquid contains: oligomeric xylose 4g in packing, polydextrose 2g, chitosan 1g, vitamin C 0.1g).
Embodiment 6
Take by weighing each component by following weight:
Oligomeric xylose 8kg, polydextrose 6kg, chitosan 4kg, vitamin C 0.5kg;
After pure water is heated to 65 ℃, add oligomeric xylose while stirring, polydextrose, chitosan, until whole dissolvings, then heating 15 minutes under 85 ℃ of temperature is cooled to room temperature, and is standby; With vitamin C with dissolved in purified water after, join in the above-mentioned steps prepared solution, stir, add pure water to the gross weight of solution and reach 100kg, stir, filter, filtrate fill, sterilization, (specification: 100ml/ props up, and every 100ml oral liquid contains: oligomeric xylose 8g in packing, polydextrose 6g, chitosan 4g and vitamin C 0.5g).
Test example 1 oral liquid toxicology test of the present invention
1 test material
1.1 for the prepared oral liquid of test agent: embodiment of the invention 1-6.The oral recommended dose of human body is 50mL/ time * 1 time/day, calculates with everyone 60kg body weight, amounts to dosage 0.833mL/kg/ days.4.2 times of concentrated solutions (proportion 1.2683g/mL) of fetching and delivering inspection are standby.
1.2 laboratory animal and environment: cleaning level Kunming mouse and SD rat that animal technical college laboratory animal plant of Agricultural University Of Hunan provides, laboratory animal production licence number are SCXK (Hunan) 2003-0003.The laboratory animal occupancy permit number is SYXK (Hunan) 2003-0002.Experimental session Animal House ambient temperature is 21 ℃-24 ℃, humidity 56%-58%.
1.3 acute oral toxicity test: adopt the test of maximum tolerance reason.Selecting body weight for use is 20 of the healthy Kunming mouses of 18g-22g, male and female half and half.Get 4.2 times of concentrated solutions of oral liquid of the present invention (proportion 1.2683g/mL) and press the disposable per os filling of 20mL/kg.bw volume stomach to mice, dosage reaches 25366mg/kg.bw.Irritate the preceding fasting of stomach 16 hours.Observed for two weeks record poisoning manifestations and death condition after irritating stomach continuously.Result of the test sees Table 1.
Table 1 oral liquid of the present invention is to the acute oral toxicity test result of mice
1.4Ames test: employing is tested through identifying satisfactory Salmonella typhimurium histidine defect type TA97, TA98, TA100, TA102 four strain bacterial strains.Five test doses are respectively 5000,1000,200,40, the 8ug/ ware, establish simultaneously from beaming back changes, solvent control (distilled water) and positive mutagens to contrast.During the sample preparation, get 4.2 times of concentrated solutions of 1.49mL oral liquid of the present invention (containing solid content 1.25g) adding distil water and be settled to 25mL, mixing is made into 5000ug/ ware concentration group and is subjected to test solution; Therefrom get the 5.0mL adding distil water and be settled to 25mL, mixing is made into 1000ug/ ware concentration group and is subjected to test solution; Be subjected to get the test solution 5.0mL adding distil water from 1000ug/ ware concentration group and be settled to 25mL, mixing is made into 200ug/ ware concentration and is organized test solution; The rest may be inferred, is made into 40,8ug/ ware concentration group is subjected to test solution, and the sterilization back is standby.Test adopts Polychlorinated biphenyls (PCB) inductive rat liver microsomes enzyme (S-9) as external metabolism activation system.Adding 0.1mL test strain enrichment liquid, 0.1mL are subjected to test solution and 0.5ml S-9 mixed liquor (when the needs metabolism activation) in top agar, pour into behind the mixing on the bottom culture medium flat plate.Cultivated 48 hours, and counted every ware clump count for 37 ℃.If the change clump count that returns of animal subject becomes more than 2 times of clump count above beaming back certainly, and the person is decided to be the positive the dose-response relationship.A whole set of test repeats to do twice under same test conditions.Result of the test sees Table 2 and table 3.
Table 2 oral liquid Salmonella reversion test of the present invention result (for the first time)
Annotate: above result is the means standard deviation of 3 plates.Positive control: TA97+S9, TA98+S9, TA100+S9 adopt 2-AF, and (dosage: 10.0 μ g/ wares): (dosage: 0.2 μ g/ ware): TA100-S9 adopts NaN to TA97-S9, TA98-S9 employing 9-Fluorenone
3(dosage: 1.5 μ g/ wares): TA102+S9 adopts 1, and (dosage: 50.0 μ g/ wares): TA102-S9 adopts MMC, and (dosage: 0.5 μ g/ ware), table 3 together for the 8-istizin.
Table 3 oral liquid Salmonella reversion test of the present invention result (for the second time)
By table 2,3 as seen, to TA97, TA98, TA100, TA102 four strain test strains, add and do not add S9, each dosage group of sample is returned and is become the bacterium colony number average above from beaming back 2 times that become clump count, does not also have dosage one reaction relation, and pointing out and being tried thing is the mutation feminine gender.
1.5 PCEMNR micronucleus test: adopt 24 hours twice per os administration by gavage at interval.Get body weight and be 50 of the healthy Kunming mouses of 25-30g, be divided into 5 groups at random, 10 every group, male and female half and half.With the positive contrast of the cyclophosphamide of 40mg/kgbw dosage, the negative contrast of distilled water.3 dosage of test group are respectively 10000,5000,2500mg/kgbw, get oral liquid of the present invention 4.2 times of concentrated solution 25.00g, 12.50g, 6.25g adding distil water standardize solution 50mL during test respectively, the cyclophosphamide positive control is got 100mg cyclophosphamide adding distil water and is settled to 50mL, presses the 0.20mL/10gbw volume to mice and irritates stomach 2 times in 24 hours at interval.Animal was put to death in cervical vertebra dislocation in 6 hours after last was given sample, got bone marrow of sternum and diluted smear with calf serum, and methanol is fixed, Giemsa dyeing.Under the optical microscope, every animal counting 1000 polychromatic erythrocytes (PCE), microkernel incidence is pressed the X2 inspection statistics and is handled to contain the PCE permillage of micronucleus.Count 200 polychromatic erythrocytes, calculate the ratio (PCE/NCE) of polychromatic erythrocyte and mature erythrocyte.
Result of the test sees Table 4, through x
2Check, each dosage group micronuclear rates of sample and negative control group comparing difference do not have significance (P＞0.05), and each dosage group and negative control group micronuclear rates significantly are lower than cyclophosphamide group (P＞0.01).Each organizes PCE/NCE ratio all in normal range.The prompting sample is not seen damaging action to bone marrow cells in mice.
Table 4 oral liquid of the present invention is to the influence of mouse bone marrow cells microkernel incidence
1.6 mouse sperm deformity test: get 25 of the male mice in kunming of body weight 25g-35g, be divided into 5 groups at random, 5 every group.With the positive contrast of the cyclophosphamide of 40mg/kgbw dosage, the negative contrast of distilled water.Three dosage of test group are respectively 10000mg/kgbw, 5000mg/kgbw, 2500mg/kgbw, get oral liquid of the present invention 4.2 times of concentrated solution 25.00g, 12.50g during test respectively, the 6.25g adding distil water is settled to 50mL, the cyclophosphamide positive control is got 100mg cyclophosphamide adding distil water standardize solution to 50mL, press the 0.20mL/10gbw volume to mice and irritate stomach, each filling while stirring.Once a day, continuous 5 days, the 30th day execution animal after last is irritated stomach, get the both sides epididymis, place the plate that is placed with the 2mL normal saline, epididymis is vertically cut the 1-2 cutter, leave standstill 3～5min with eye scissors, swing gently, filter with four layers of lens paper, suction strainer liquid smear, dry back methanol is 5min fixedly, 2% Yihong dyeing 1h, water gently dashes, drying.The sperm of 1000 structural integrities of every animal counting, counting distortion spermatogenesis rate.Press x
2Inspection statistics is handled.
Result of the test sees Table 5.Through x
2Check, each dosage group rate of teratosperm of sample and negative control group comparing difference do not have significance (P＞0.05), and each dosage group and negative control group rate of teratosperm significantly are lower than cyclophosphamide group (P＜0.01).China's rain board clears the snow clearly, and oral liquid does not produce the distortion effect to mouse sperm.
Table 5 oral liquid of the present invention is to the influence of mouse sperm deformity incidence rate
1.7 30 days feeding trials:
1.7.1 the dosage group selection with tried thing and given mode: 80 of SD rats, male and female half and half, male Mus body weight 72.3 ± 5.5g, male Mus body weight 73.4 ± 5.5g.Be divided into four groups at random, promptly matched group and three are tried the thing group, and 20 every group, male and female half and half.The basic, normal, high dosage of oral liquid of the present invention is respectively 41.67mL/Kgbw, 62.50mL/Kgbw, 83.33mL/Kgbw, is equivalent to 50,75,100 times of human body recommended dose respectively.Low, middle dosage is subjected to that the test solution preparation time is got 4.2 times of concentrated solution 99.2mL of oral liquid of the present invention respectively, the 148.8mL adding distil water is settled to 200mI, press the 2.0mL/100gbw volume to rat and irritate stomach, the high dose group rat is adopted 4.2 times of concentrated solutions directly to press the 2.0mL/100gbw volume to rat and irritates stomach, matched group is irritated stomach and is given the equal-volume distilled water, once a day, continuous 30 days.
1.7.2 key instrument and reagent: key instrument: the CD of Abbott Laboratories 3700 full-automatic blood counting instruments, OLYMPUSAU400 automatic clinical chemistry analyzer, TD5A-WS table-type low-speed centrifuge etc.Main agents: total protein (TP), albumin (ALB), blood urea nitrogen (BUN), blood glucose (GLU) test kit are available from Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.: glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) are available from Shanghai Foxing Changzheng medical science Co., Ltd: creatinine (Cr) can a Diagnostic Technologies Ltd. of DESAY available from the Shen, Shanghai; Cholesterol (CHOL), triglyceride (TG) are available from east, Zhejiang bowl biological engineering company limited.
1.7.3 experimental technique: all animals of experimental session give normal diet, single cage is raised, the drinking-water of freely ingesting, observe activity and the growing state of animal every day, add food 2 times weekly, appetite and surplus appetite given in record, claims body weight weekly one time, calculate weekly food-intake and food utilization, the total foodstuff utilization rate is calculated at the experiment end.Test latter stage, after the fasting 14 hours, every rat is plucked eyeball and gathers two parts of blood: anticoagulation is measured hemoglobin (Hb), packed cell volume (HCT) with the full-automatic blood counting instrument of the CD3700 of Abbott Laboratories, carries out erythrocyte (RBC), leukocyte (WBC), platelet (PLT) counting and WBC classification; Non-anticoagulation leaves standstill the back separation of serum, divides instrument to measure TP, ALB, ALT, Cr, BUN, AST, CHOL, TG and GLU with OLYMPUS AU400 full-automatic biochemical.The cervical vertebra dislocation of blood sampling back is put to death animal and is done gross anatomy, claims liver,kidney,spleen, testicular weight, calculates dirty/body ratio, gets liver,kidney,spleen, stomach, duodenum, testis, ovary and does the pathology cut sections for microscopic examination.When inspection does not find that obvious pathological changes and biochemical indicator change substantially to each dosage treated animal work, only carry out the histopathological examination of maximum dose level group and control animals main organs, as finding that pathological changes is then to checking than low dose group corresponding organ and tissue.
1.7.4 experimental data statistics: carry out data conversion and statistical analysis with ExceI, Spss, Instat software.During with the Spss software analysis, earlier data are carried out homogeneity test of variance, if variance is neat, adopt one factor analysis of variance totally to compare, the reuse Dunnett method that finds differences is carried out comparing in twos between a plurality of dosage groups and matched group mean.If heterogeneity of variance then carries out the conversion of suitable variable to initial data, satisfy homogeneity test of variance after, add up with the data after changing; If do not reach the neat purpose of variance yet after the variable conversion, to use rank test instead and add up, discovery is overall more variant, then adopts Tamhan ' the esT2 check that does not require homogeneity of variance to compare in twos.During feeding in 30 days, each animal growth is good, and no abnormal behavior and poisoning symptom do not have dead.Result of the test sees Table 6-20.
1.7.5 experimental result:
1.7.5.1 oral liquid of the present invention is to the influence of rat body weight and body weight gain
Table 6 oral liquid of the present invention is to the influence of rat body weight and body weight gain
Through the check of variance homogeneous school, each time point body weight of female, male Mus and duration of test weight gain value variance are neat, adopt one factor analysis of variance to add up, and the result does not see significant difference (P＞0.05) between each dosage group and the matched group.
1.7.5.2 oral liquid of the present invention is to the influence of rats eating amount and food utilization
Result of the test sees Table 7.Through the variance test of homogeneity, male Mus the 2nd, 4 all food-intakes, male and female Mus the 1st all food utilization heterogeneity of variances, adopt rank test, other weeks of female, male Mus and total food-intake, other weeks and total foodstuff utilization rate variance are neat, adopt one factor analysis of variance to add up, the result shows between each dosage group and the contrast each all and total food-intake, food utilization there was no significant difference (P＞0.05).
Table 7 oral liquid of the present invention is to the influence of rats eating amount
1.7.5.3 oral liquid of the present invention is to the influence of rat food utilization
Table 8 oral liquid of the present invention is to the influence of rat food utilization
1.7.5.4 oral liquid of the present invention is learned the influence of index to rat blood
Result of the test sees Table 9-10.Female Mus hemoglobin, packed cell volume heterogeneity of variance are shown in homogeneity test of variance, adopt rank test, it is neat that each organizes male and female rat leukocyte, erythrocyte, total number of blood platelet, leukocyte differential count variance, adopt one factor analysis of variance to add up, the result shows each dosage group and the above-mentioned every index there was no significant difference of matched group (P＞0.05).
Table 9 oral liquid of the present invention feeding trial hematological examination in 30 days result
30 days feeding trials of table 10 oral liquid of the present invention are to the influence of leukocyte differential count
1.7.5.5 oral liquid of the present invention is to the influence of rat biochemical indicator
Result of the test sees Table 11 and table 12.Homogeneity test of variance shows that the every biochemical indicator mean square deviation of male and female Mus is neat, adopts one factor analysis of variance to carry out statistical disposition, and the result shows every biochemical indicator there was no significant difference (P＞0.05) between each dosage group and the matched group.
30 days feeding trials of table 11 oral liquid of the present invention biochemical investigation in latter stage result
30 days feeding trial arts of table 12 oral liquid of the present invention phase biochemical investigation result
1.7.5.6 oral liquid of the present invention is to the influence of Rats Organs and Tissues absolute weight and internal organs/body weight ratio
Result of the test sees Table 13-14.Through the variance test of homogeneity, each organize male and female rat liver, spleen, kidney, male Mus testis absolute weight and and testis/body weight ratio variance of liver/body, spleen/body, kidney/body ratio and male Mus neat, adopt one factor analysis of variance to carry out statistical analysis, the result shows that each internal organs absolute weight and dirty body ratio are than there was no significant difference (P＞0.05) between each dosage group and the corresponding matched group.
Table 13 oral liquid of the present invention is to the influence of Rats Organs and Tissues absolute weight
Table 14 oral liquid of the present invention is to the influence of the dirty body ratio of rat
1.7.5.7 gross anatomy and histological examination result
When each dosage treated animal being done the gross anatomy inspection, do not find obvious pathological changes, only carry out the histopathological examination of high dose group and control animals main organs.The tissue pathological slice check result sees Table 15-21.
Table 15 liver organization pathological examination result
Annotate: pathological changes (as follows) appears in 1 animal in 10 animals of 1/10 expression, and above pathological changes appears at same rat
Table 16 spleen tissue pathological examination result
Table 17 renal tissue pathological examination result
Table 18 gastric tissue pathological examination result
Table 19 duodenum histopathological examination result
The female Mus ovary tissue of table 20 pathological examination result
The male Mus testis tissue of table 21 pathological examination result
3 conclusion (of pressure testing)s
3.1 acute oral toxicity test
Do not see obvious poisoning symptom behind the Kunming mouse filling stomach of 4.2 times of concentrated solutions of oral liquid of the present invention with 25366mg/kgbw dosage, observe and do not have death in 14 days to two kinds of sexes.Oral liquid of the present invention to the acute oral toxicity test maximum tolerated dose (MTD) of female, male Kunming mouse greater than 25366mg/kgbw (seeing Table 1).Acute toxicity grading criteria according in " health food check and assessment technique standard " (version in 2003) belongs to non-poisonous material.
3.2 genetic toxicity test: the result is all negative for three genetic toxicity tests (Salmonella reversion test, PCEMNR micronucleus test and mouse sperm deformity test).
3.3 30 days feeding trials: the oral liquid of the present invention with 41.67mL/kgbw, 62.50mL/kgbw, 83.33mL/kgbw dosage (be equivalent to respectively human body recommended amounts 50,75,100 times) was irritated stomach 30 days to rat oral, experimental session, each treated animal growth promoter is good, and each dosage of sample is to rat body weight, body weight gain, average food-intake and food utilization do not make significant difference (P＞0.05).The experiment end, each dosage group hematological indices (hemoglobin, erythrocyte sum, packed cell volume, total number of blood platelet, total white blood cells and classification), blood biochemistry index (serum glutamic pyruvic transminase, glutamic oxaloacetic transaminase, GOT, total protein, albumin, cholesterol, glycosides oil three esters, carbamide helium, creatinine, blood glucose), dirty body ratio (testis nine/body weight ratio of liver/body, spleen/body, kidney/body ratio and male Mus) and corresponding matched group relatively, there was no significant difference (P＞0.05).Gross anatomy is not seen the abnormal change relevant with sample with tissue pathology checking.Result of the test explanation oral liquid of the present invention was fed rat is had no side effect in 30 days.
The 2 oral liquid auxiliary antilipemic effect zooperies of the present invention of test example
1, material and method
The oral liquid that 11 given the test agent: embodiment of the invention 1-6 is prepared.The oral recommended dose of human body is 50mL/ time x1 time/day, calculates with everyone 60kg body weight, amounts to dosage 0.833mL/kg/ days.
1.2 laboratory animal: 40 of the cleaning level male SD rats that animal technical college laboratory animal plant of Agricultural University Of Hunan (the laboratory animal production licence number is SCXK (Hunan) 2003-0003) provides, body weight 187.7 ± 28.9g.The experimental session ambient temperature is 21 ℃-24 ℃, humidity 56%～58%, and the laboratory animal occupancy permit number is SYXK (Hunan) 2003-0002.
1.3 dosage is selected: test divides four groups: high fat matched group and basic, normal, high dosage group.Basic, normal, high dosage is respectively 4.17,8.33,16.66mL/kg.bw (be equivalent to respectively human body recommended amounts 5,10,20 times), get oral liquid stock solution 41.7mL of the present invention, 83.3mL during test respectively, the 166.6mL adding distil water is settled to 200mL, be mixed with the test solution that is subjected to of respective concentration, press the 2.0mL/100g.bw volume and give rat oral gavage, once a day, continuous 30 days.Matched group is irritated stomach and is given the equal-volume distilled water.
1.4 key instrument and reagent: OLYMPUS AU400 automatic clinical chemistry analyzer; Cholesterol (CHOL), triglyceride (TG), high density lipoprotein (HDL-C) test kit are provided by Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
1.5 high lipid food: normal feedstuff 78.8%, cholesterol 1%, yolk powder 10%, Adeps Sus domestica 10%, cholate 0.2%.
1.6 experimental technique: after one week of normal feedstuff feed rat, fasting 14 hours, get tail blood, measure serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) with OLYMPUS AU400 automatic clinical chemistry analyzer, according to the TC level chin or cheek TG that holds concurrently animal is divided into 4 groups at random: high fat matched group and three are tried the thing group.Begin from formal test, each treated animal is used high lipid food instead, is tried the thing group and irritates the oral liquid of the present invention that stomach gives various dose by dosage design in 1.3, high fat matched group filling stomach gives the distilled water with volume, after continuous 30 days, fasting 14 hours is pulled out the eyeball blood sampling and is measured every blood lipids index.
1.7 imitate according to processing
Carry out data transaction and statistical analysis with Excel, Spss software.When carrying out statistical analysis with Spss software, earlier data are carried out homogeneity test of variance, if variance is neat, adopt one factor analysis of variance totally to compare, the reuse Dunnett method that finds differences is carried out comparing in twos between a plurality of dosage groups and matched group mean.If heterogeneity of variance, then initial data is carried out suitable variable conversion, after satisfying homogeneity test of variance, add up with the data after the conversion: if do not reach the neat purpose of variance yet after the variable conversion, using rank test instead adds up, discovery is overall more variant, then adopts the Tamhane ' sT2 check that does not require homogeneity of variance to compare in twos.Serum total cholesterol before and after the test. triglyceride, the solid liquor-saturated t check of relatively adopting paired comparison of high density lipoprotein gallbladder.
1.8 the result judges
1.8.1 the auxiliary lipid-lowering function result judges: in serum total cholesterol, triglyceride, HDL-C detect, serum total cholesterol, the triglyceride binomial index positive, this given the test agent auxiliary lipid-lowering function zoopery of decidable is the positive as a result.
1.8.2 auxiliary triglyceride reducing result judges: 1. two dosage groups of triglyceride positive as a result; 2. dosage group of triglyceride positive as a result, HDL-C is significantly higher than matched group simultaneously, and the auxiliary triglyceride reducing zoopery of this given the test agent of decidable is the positive as a result.
1.8.3 the auxiliary serum total cholesterol result that reduces judges: 1. two dosage groups of serum total cholesterol positive as a result: 2. dosage group of serum cholesterol positive as a result, HDL-C is significantly higher than matched group simultaneously, the auxiliary serum total cholesterol zoopery positive as a result that reduces of this given the test agent of decidable.
2 result of the tests
2.1 oral liquid of the present invention is to the influence of rat body weight
Duration of test, the growth of each treated animal is normal. and the initial body weight of each dosage treated animal, mid-term, body weight, whole opisthosoma heavily reached weightening finish and high fat matched group relatively, there was no significant difference (P＞0.05 sees Table 22).
Table 22 oral liquid of the present invention is to the influence of rat body weight
2.2 influence to Serum TC, TG, HDL-C
Homogeneity test of variance shows that serum TC before and after the test of each treated animal, TG, HDL-C variance are neat, paired t-test shows that high fat control animals test back serum TC, TG are significantly higher than test preceding (all P=0.001), prompting modeling success. the oral liquid of the present invention with various dose is given rat oral gavage 30 days, compare with high fat matched group, 4.17ml/kg.bw dosage can significantly reduce high lipid food Serum TC, the TG level (P＜0.05) (table 23,24) of raising; 4.17,8.33,16.66mL/kg.bw, dosage group serum TC descends respectively by 24.3%, 14.2% and 12.7% (table 23), TG descends respectively by 41.2%, 31.1% and 22.0% (table 24). sample does not make significant difference to the Serum HDL-C level; (P＞0.05) (table 25).
Respectively organize the serum TC level before and after table 23 experiment
Respectively organize the serum TG level before and after table 24 experiment
Respectively organize the Serum HDL-C level before and after table 25 experiment
3 brief summaries
With 4.17,8.33, the given the test agent of 16.66mL/kg.bw dosage gives rat oral gavage 30 days, compare with high fat matched group, 4.17mL/kg.bw dosage can significantly reduce and raise high lipid food Serum TC, TG level (P＜0.05=, each dosage is to rat blood serum HDL-C level do not make significant difference (P＞0.05).The zoopery of prompting given the test agent blood-fat-decreasing is the positive as a result.
Adopt counter point between own control and group, selection meets the trial volunteer of experimental condition and takes given the test agent after 45 days, the result shows: take given the test agent test-meal group self paired comparison, compare before CHOL, TG and the test-meal after the test group test-meal, the difference significance (P＜0.05 or P＜0.01 〉, test-meal group CHOL, TG and matched group compare after the test-meal, the difference significance (P＜0.05 or P＜0.01 〉.And test-meal group HDL-C and matched group comparing difference do not have significance (P＞0.05) after the test-meal.Experimental result shows that given the test agent has good auxiliary lipid-lowering function.
The 3 oral liquid effect for reducing blood fat human experiment experiments of the present invention of test example
1 material and method
1.1 sample
1.1.1 supply test agent: the oral liquid (50.0mL/ props up) that the embodiment of the invention is prepared.
1.1.2 control sample: placebo (forming) (50.0mL/ props up) by distilled water is prepared.
1.2 the experimenter selects
1.2.1 the standard of including in, the experimenter is selected from XianJiaHu, Yuelu District, ChangSha City, HuNan Province community, male or female.Age 18-65 year, physical condition is good, does not have obvious brain, the heart, liver, lung, kidney, blood illness, does not have the history of taking medicine for a long time, and aspiration is subjected to examination to guarantee to cooperate.
1.2.2 experimenter's exclusion standard: gestation or women breast-feeding their children, to the health food allergy sufferers; Merge to have the inclination, serious disease patients such as liver, kidney and hemopoietic system: take the article relevant in a short time, have influence on judgement person as a result with being tried function; Do not meet the standard of including in, edible in accordance with regulations given the test agent can't be judged effect or data not umbra sound effect or safety judgement person.
1.3 experimental design and grouping
Adopt two kinds of control design between self and group.Be divided at random for test agent test-meal group and placebo group by experimenter's blood lipid level, consider to influence result's principal element such as age, sex etc. as far as possible, carry out the harmony check, with the comparability between the assurance group.Carry out the test-meal test by double-blind method.
1.4 test method
The experimenter is on the October 16th, 2004 of blood sampling survey for the first time blood fat, and the dyslipidemia person took a blood sample for the second time on 01 18th, 2005 and surveys blood fat, and twice all unusual person includes test in, test in beginning on 01 20th, 2005, the experimenter takes and supply test agent 1 time every day, each 1, takes continuously 45 days.Duration of test does not change original dietary habit, normal diet.
2. observation index
Each measures once every observation index when test-meal on-test and end.
2.1 safety indexes
2.1.1 general physical examination: perquisition and understand experimenter's situations such as spirit, sleep, diet, defecation, blood pressure before the test.
2.1.2 routine blood test: red blood cell count(RBC), numeration of leukocyte and classification, content of hemoglobin mensuration etc.
2.1.3 routine urinalysis: pH value, leukocyte, glucose in urine etc.
2.1.4 stool for routine.
2.1.5 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line are checked.
2.1.6 liver function test: total serum protein (TP), albumin (ALB), glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) are measured.
2.1.7 kidney function test: serum urea nitrogen (BUN), creatinine (Cr), blood glucose (GLU) are measured.
2.2 effect index: cholesterol (CHOL), triglyceride (TG), HDL-C (HDL-C)
3. the result judges
3.1CHOL reduce＞10%; TG reduces＞15%; HDLC rising＞0.104mmol/L; Between group statistical significance is arranged more all after each effect observation index test front and back self comparison and the test-meal, can judge this index positive;
3.2 serum cholesterol, the triglyceride binomial index positive, HDL-C significantly is not lower than matched group, and the decidable given the test agent has the auxiliary lipid-lowering function effect; Positive in serum cholesterol, the triglyceride binomial index, HDL-C significantly is not lower than matched group, and the decidable given the test agent has auxiliary reduce serum cholesterol or auxiliary triglyceride reducing effect.
4. statistical procedures
Data result represents with mean ± standard deviation, self paired data adopts paired t-test, between test group and the matched group under the prerequisite of homogeneity of variance, mean relatively adopts t check in groups, otherwise adopt the t check after carrying out satisfying homogeneity of variance after variable transforms, if variance is still uneven, adopt rank test.
5. result
Double-blind method is observed and is finished to make known; Take No. 2 persons for the magnificent rain board oral liquid clearly that clears the snow, take No. 1 person and be placebo.
5.1 safety is observed
5.1.1 ordinary circumstance: test-meal group 54 examples, matched group 54 examples.After test in 45 days, test group has 4 routine experimenters because of can't judging that curative effect is screened out, and matched group has 2 routine experimenters to take because of interruption screened out by test product.Last efficiency test crowd test group 50 examples, matched group 52 examples.Before and after the test-meal, experimenter's mental status, sleep state, defecation situation no abnormality seen; Routine urinalysis, stool routine examination there is no unusually the test-meal group before and after the test-meal: man/woman is 26/24, the age 40.52 ± 8.76; Matched group: man/woman is 25/27, and the age is 41.12 ± 8.36.
5.1.2 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line detect: all in normal range.
5.1.3 routine blood test index situation of change before and after the test-meal test
Forward and backward test-meal group of test-meal sample and matched group routine blood test changing value be in normal range (table 26) all.
Routine blood test index situation of change before and after the table 26 test-meal test
5.1.4 liver function index situation of change before and after the test-meal test
Forward and backward test-meal group of test-meal sample and matched group total serum protein (TP), serum albumin (ALB), glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) be in range of normal value (table 27) all.
Liver function index situation of change before and after the table 27 test-meal test
5.1.5 renal function index situation of change before and after the test-meal test
Forward and backward test-meal group of test-meal sample and matched group serum creatinine (Cr), blood glucose (GLU), serum urea nitrogen (BUN) be in range of normal value (table 28) all.
Renal function index situation of change before and after the table 28 test-meal test
5.1.6 effect is observed
Before and after the test-meal test change of serum C HOL, the horizontal situation of change of TG, HDL-C see Table 29, table 30 and table 31.Before the test, matched group and test-meal group change of serum C HOL, TG, HDL-C level compare, and not statistically significant points out between two groups to have comparability.After the test, self relatively, after the test-meal of test-meal group before CHOL, TG and the test-meal relatively, difference have the significance meaning (P＜0.05 or P＜0.01 〉, after the matched group test-meal before CHOL, TG and the test-meal comparing difference do not have significance (P＞0.05).After the test-meal test-meal group CHOL, TG and matched group relatively, difference have the significance meaning (P＜0.05 or P＜0.01 〉.And test back test-meal group HDL-C and matched group comparing difference do not have significance (P＞0.05).Prompting has auxiliary lipid-lowering function preferably for test agent.
Change of serum C HOL, TG, the horizontal situation of HDL-C before the table 29 test-meal test
Change of serum C HOL, the horizontal situation of change of TG, HDL-C before and after the table 30 test-meal test
Annotate:
*With comparison P＜0.05 before the test-meal
*With comparison P＜0.01 before the test-meal
# and matched group compare P＜0.05 ## and matched group compares P＜0.01
Change of serum C HOL, TG, HDL-C rate of change before and after table 31 test-meal
6. brief summary
Adopt counter point between own control and group, selection meets the trial volunteer of experimental condition and takes for the examination thing after 45 days, the result shows: take for test agent test-meal group self paired comparison, compare before CHOL, TG and the test-meal after the test group test-meal, difference have the significance meaning (P＜0.05 or P＜0.01 〉, after the test-meal test-meal group CHOL, TG and matched group relatively, difference have the significance meaning (P＜0.05 or P＜0.01 〉.And test-meal group HDL-C and matched group comparing difference do not have significance (P＞0.05) after the test-meal.Result of the test shows that oral liquid of the present invention has definite blood fat reducing function.
Claims (7)
1. oral administration liquor for reducing blood fat, it is characterized in that: per 100 milliliters of these oral liquids contain each component of following weight:
Oligomeric xylose 4-8g, polydextrose 2-6g, chitosan 1-4g and vitamin C 0.1-0.5g.
2. according to the oral administration liquor for reducing blood fat of claim 1, it is characterized in that: per 100 milliliters of these oral liquids contain each component of following weight: oligomeric xylose 6g, polydextrose 4g, chitosan 2.7g, vitamin C 0.3g.
3. according to the oral administration liquor for reducing blood fat of claim 1, it is characterized in that: per 100 milliliters of these oral liquids also contain each component of following weight: maltose 2-6g, fruit Fructus Vitis viniferae slurry 2-6g, Mel 2-4g, citric acid 0.5-2g, lactic acid 0.05-0.5g and grapefruit essence 0.05-0.5g.
4. according to the oral administration liquor for reducing blood fat of claim 3, it is characterized in that: per 100 milliliters of these oral liquids contain each component of following weight: maltose 4g, fruit Fructus Vitis viniferae slurry 4g, Mel 3g, citric acid 1g, lactic acid 0.1g, grapefruit essence 0.1g.
5. method for preparing claim 1 oral administration liquor for reducing blood fat may further comprise the steps:
(1) takes by weighing each component by following weight: oligomeric xylose 4-8g, polydextrose 2-6g, chitosan 1-4g and vitamin C 0.1-0.5g;
(2) pure water is heated to 60-70 ℃ after, add oligomeric xylose while stirring, polydextrose and chitosan are until whole dissolvings;
(3) the resulting solution of step (2) was heated 10-20 minute under 80-90 ℃ of temperature, be cooled to room temperature, standby;
(4) with vitamin C with dissolved in purified water after, join in step (3) prepared solution, stir, add pure water to 100ml, stir, filter, filtrate fill, sterilization, promptly.
6. according to the method for claim 5, it is characterized in that: after in the step (2) pure water being heated to 65 ℃, add oligomeric xylose while stirring, polydextrose and chitosan.
7. according to the method for claim 5, it is characterized in that: in the step (3) the resulting solution of step (2) was heated 15 minutes under 85 ℃ of temperature, be cooled to room temperature again, standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610170477XA CN100393321C (en) | 2006-12-30 | 2006-12-30 | Oral antilipemic liquid and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610170477XA CN100393321C (en) | 2006-12-30 | 2006-12-30 | Oral antilipemic liquid and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1985845A CN1985845A (en) | 2007-06-27 |
| CN100393321C true CN100393321C (en) | 2008-06-11 |
Family
ID=38182872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610170477XA Expired - Fee Related CN100393321C (en) | 2006-12-30 | 2006-12-30 | Oral antilipemic liquid and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100393321C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653283B (en) * | 2009-09-10 | 2012-10-17 | 张树文 | Chitosan oligosaccharide drinking water |
| CN102415526A (en) * | 2011-12-09 | 2012-04-18 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide-containing health food |
| CN107960662A (en) * | 2017-11-03 | 2018-04-27 | 嘉必优生物技术（武汉）股份有限公司 | A kind of health products with hypolipemic function and preparation method thereof |
| CN108498531A (en) * | 2018-06-01 | 2018-09-07 | 广东药科大学 | A kind of chitosan oral solution and preparation method thereof |
| CN109588672A (en) * | 2019-02-18 | 2019-04-09 | 江西汪氏蜜蜂园有限公司 | A kind of allotment queen bee pulp beverage and its preparation process |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452903A (en) * | 2003-05-22 | 2003-11-05 | 穆运转 | Compound organic silk as antioxidant, anti-senility and heavy metal pollution-resisting health food |
-
2006
- 2006-12-30 CN CNB200610170477XA patent/CN100393321C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452903A (en) * | 2003-05-22 | 2003-11-05 | 穆运转 | Compound organic silk as antioxidant, anti-senility and heavy metal pollution-resisting health food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1985845A (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101606706B (en) | Health food prepared from compound bee product raw materials | |
| DE60210604T2 (en) | POLYMER-CONTROLLED INDUCED VISCOSES BRAZING SYSTEM AND ITS USES | |
| EP0464299B1 (en) | Antihypertensive preparation | |
| CN105795468A (en) | Composition having efficacy of losing weight | |
| CN102215850B (en) | Composition containing fucoxanthin extract | |
| CN103284039A (en) | Weight-reducing composition and preparation method thereof | |
| CN100393321C (en) | Oral antilipemic liquid and its preparing method | |
| CN100420391C (en) | Health-care food with anti-oxidation and lowering weight functions | |
| CN101415429B (en) | Lipopexia inhibitor | |
| CN101683477A (en) | Composition for fat-reducing | |
| CN103861086A (en) | Preparation method of bitter gourd peptide arabinose composite tablet | |
| EP0431650A1 (en) | A substance having suppressing function for diseases relating to increase in cholesterol, and foods and drinks in which it is used | |
| CN104938684A (en) | Tea for assisting reduction of blood lipid and preparation method thereof | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN103566198A (en) | Application of gastrodia elata and gastrodin in preparation of product used for treating non-alcoholic fatty liver disease | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN109892555A (en) | A kind of diet food and preparation method thereof for hindering Fatty synthesis to accelerate oil extraction fat reducing | |
| CN100372541C (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
| CN110432500A (en) | A kind of prebiotic compositions and preparation method and purposes containing inulin | |
| EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) | Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post‐prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro‐intestinal microorganisms (ID 1558) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006 | |
| CN101912407A (en) | Weight-reducing and lipid-lowering composition | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect | |
| CN109157584A (en) | A kind of composition and its preparation method and application with auxiliary lipid-lowering function | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20150910 Granted publication date: 20080611 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20160310 Granted publication date: 20080611 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160415 Address after: 150000 science and Technology Innovation Zone, Harbin hi tech Industrial Development Zone, building 19, building 699, innovation road, No. 1, Heilongjiang Patentee after: Harbin everything Wo Wo Health Science and Technology Co., Ltd. Address before: 150221 Wuchang City in Heilongjiang Province town of Hua Yulu No. 1 cattle Patentee before: Huayu Pharmaceutical Group Corp., Ltd., Harbin |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190723 Address after: 150 000 No. 47 Huahong Road, Nangang District, Harbin City, Heilongjiang Province Patentee after: Hua Tao Address before: 150000 science and Technology Innovation Zone, Harbin hi tech Industrial Development Zone, building 19, building 699, innovation road, No. 1, Heilongjiang Patentee before: Harbin everything Wo Wo Health Science and Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080611 Termination date: 20191230 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |